Search research articles
Contact Us
Filters
Showing results (1-10 of 4) with videos related to
Page
of 1
Sort By:
The New England Journal of Medicine
|
March 31, 2017
Myasthenia Gravis
Sabina Miranda, Derrece K Reid, Christy S John
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
December 7, 2002
Sigma receptor scintigraphy with N-[2-(1'-piperidinyl)ethyl]-3-(123)I-iodo-4-methoxybenzamide of patients with suspected primary breast cancer: first clinical results
Vicky Caveliers, Hendrik Everaert, Christy S John, et al.
Expert Opinion on Drug Delivery
|
August 27, 2016
Phase-0/microdosing studies using PET, AMS, and LC-MS/MS: a range of study methodologies and conduct considerations. Accelerating development of novel pharmaceuticals through safe testing in humans - a practical guide
Tal Burt, Christy S John, Jon L Ruckle, et al.
The Oncologist
|
April 14, 2018
FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia
Kelly J Norsworthy, Chia-Wen Ko, Jee Eun Lee, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 4) with videos related to
Sort By:
Page
of 1
The New England Journal of Medicine
|
March 31, 2017
Myasthenia Gravis
Sabina Miranda, Derrece K Reid, Christy S John
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
December 7, 2002
Sigma receptor scintigraphy with N-[2-(1'-piperidinyl)ethyl]-3-(123)I-iodo-4-methoxybenzamide of patients with suspected primary breast cancer: first clinical results
Vicky Caveliers, Hendrik Everaert, Christy S John, et al.
Expert Opinion on Drug Delivery
|
August 27, 2016
Phase-0/microdosing studies using PET, AMS, and LC-MS/MS: a range of study methodologies and conduct considerations. Accelerating development of novel pharmaceuticals through safe testing in humans - a practical guide
Tal Burt, Christy S John, Jon L Ruckle, et al.
The Oncologist
|
April 14, 2018
FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia
Kelly J Norsworthy, Chia-Wen Ko, Jee Eun Lee, et al.
Page
of 1